Sangamo Therapeutics’ (SGMO) Sector Perform Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada restated their sector perform rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a $2.00 price target on the biopharmaceutical company’s stock.

Several other analysts also recently issued reports on the stock. Wells Fargo & Company reduced their price target on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 31st. StockNews.com downgraded shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Jefferies Financial Group reduced their price target on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, December 31st. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a report on Monday, January 27th. Finally, Truist Financial reduced their price target on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $5.17.

Sangamo Therapeutics Trading Down 3.5 %

Shares of SGMO opened at $0.84 on Tuesday. The firm’s 50-day moving average is $1.07 and its two-hundred day moving average is $1.40. Sangamo Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.18. The firm has a market capitalization of $175.08 million, a P/E ratio of -1.12 and a beta of 1.49.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The company had revenue of $7.55 million for the quarter, compared to analyst estimates of $11.70 million. Analysts predict that Sangamo Therapeutics will post -0.46 EPS for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of SGMO. Point72 Asset Management L.P. purchased a new position in shares of Sangamo Therapeutics during the fourth quarter valued at approximately $2,316,000. Schonfeld Strategic Advisors LLC purchased a new position in Sangamo Therapeutics during the fourth quarter worth approximately $1,744,000. Acuta Capital Partners LLC purchased a new position in Sangamo Therapeutics during the fourth quarter worth approximately $755,000. Two Sigma Advisers LP purchased a new position in Sangamo Therapeutics during the fourth quarter worth approximately $722,000. Finally, Two Sigma Investments LP raised its stake in Sangamo Therapeutics by 222.1% during the fourth quarter. Two Sigma Investments LP now owns 1,012,640 shares of the biopharmaceutical company’s stock worth $1,033,000 after purchasing an additional 698,296 shares during the period. Hedge funds and other institutional investors own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.